Bromocriptine formulations
The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
1. A dosage form comprising:
bromocriptine and one or more excipients;
wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject;
wherein the bromocriptine has a DV90 less than 15 μm and Dv10 of less than 2 μm; and
wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.
2. The dosage form of claim 1 , wherein the bromocriptine is in the form of a salt of bromocriptine.
3. The dosage form of claim 1 , wherein the bromocriptine is in the form of bromocriptine mesylate.
4. The dosage form of claim 1 , wherein the dosage form is in the form of a tablet.
5. The dosage form of claim 1 , wherein the excipients are selected from the group consisting of an antioxidant, a filler, a disintegrating agent, a water scavenging agent and a lubricant and mixtures thereof.
6. The dosage form of claim 4 , wherein the excipients are selected from the group consisting of citric acid, corn starch, lactose filler, silicon dioxide and magnesium stearate and mixtures thereof.
7. The dosage form of claim 1 wherein the bromocriptine is micronized.
8. The dosage form of claim 1 wherein the dosage form has a volume based particle size distribution with a span of about 2 or lower.
9. The dosage form of claim 1 , wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.
10. The dosage form of claim 1 , wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 μm.
11. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 1 .
12. The method of claim 11 , wherein the dosage form is administered in the morning within about two hours after waking.
13. A dosage form comprising:
bromocriptine and one or more excipients;
wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject;
wherein the bromocriptine has a Dv90 of about 15 μm or lower, a Dv50 of about 8 μm or lower and a Dv10 of about 3 μm or lower; and
wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.
14. The dosage form of claim 13 , wherein the bromocriptine is in the form of a salt of bromocriptine.
15. The dosage form of claim 13 , wherein the bromocriptine is in the form of bromocriptine mesylate.
16. The dosage form of claim 13 , wherein the dosage form is in the form of a tablet.
17. The dosage form of claim 13 , wherein the excipients are selected from the group consisting of an antioxidant, a filler, a disintegrating agent, a water scavenging agent and a lubricant and mixtures thereof.
18. The dosage form of claim 16 , wherein the excipients are selected from the group consisting of citric acid, corn starch, lactose filler, silicon dioxide and magnesium stearate and mixtures thereof.
19. The dosage form of claim 13 wherein the bromocriptine is micronized.
20. The dosage form of claim 13 wherein the dosage form has a volume based particle size distribution with a span of about 2.5 or lower.
21. The dosage form of claim 13 , wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.
22. The dosage form of claim 13 , wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 μm.
23. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 13 .
24. The method of claim 13 , wherein the dosage form is administered in the morning within about two hours after waking.